Many modern cancer treatments are highly effective at reducing or eliminating tumors, but they can also cause severe gastrointestinal symptoms that impact patients’ quality of life or lead to discontinuation of treatment. A new analysis from University of Illinois Urbana-Champaign researchers reveals the nutrition therapies that are most effective at minimizing GI distress. 

Researchers have reported results from the first-ever clinical trial of a new class of targeted therapy in pet cats with head and neck squamous cell carcinoma (HNSCC)—a cancer which is notoriously deadly and difficult to treat. Publishing in the Cell Press journal Cancer Cell on August 28, the study found that 35% of the cats who received treatment had their disease controlled with minimal side effects—and the drug will likely be effective for humans with HNSCC as well. 

BUFFALO, NY — August 28, 2025 — A new research paper was published in Volume 12 of Oncoscience on July 31, 2025, titled “Burnout among oncology nurses and technicians in Morocco: Prevalence, risk factors, and structural equation modeling.”

A multi-institutional trial led by UNC Lineberger Comprehensive Cancer Center researchers found that a single infusion of autologous tumor-infiltrating lymphocyte (TIL) therapy stabilized metastatic head and neck squamous cell carcinoma in some patients who had not responded to multiple prior treatments. The study demonstrated the feasibility of consistently generating TILs from recurrent and or metastatic head and neck squamous cell carcinoma tumors to stabilize a patient’s disease.

In a new study published in the Proceedings of the National Academy of Sciences, University of Michigan researchers identified cellular features that determine whether tumor cells respond to treatment. 

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer, largely driven by mutations in the KRAS gene—once considered impossible to target.